Schizophrenia News and Research

Latest Schizophrenia News and Research

NIH awards Aestus $2M SBIR grant for clinical trials of treatment for chronic neuropathic pain

Aestus Therapeutics, Inc. announced that it has been awarded a $2 million Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH). The grant, from the NIH's National Institute of Neurological Disorders and Stroke (NINDS), will fund clinical trials of Aestus's novel, first-in-class treatment for chronic neuropathic pain.

9 Jun 2010

Secondhand smoke exposure associated with psychological distress

Exposure to secondhand smoke appears to be associated with psychological distress and the risk of future psychiatric hospitalization among healthy adults, according to a report posted online today that will appear in the August print issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

8 Jun 2010

FSPs designed to improve residential stability, mental health outcomes for homeless persons with mental illness

Full-Service Partnerships are designed to do 'whatever it takes' to improve residential stability and mental health outcomes for homeless persons with serious mental illness. They are the cornerstone of California's Mental Health Services Act - one of the largest mental health policy experiments in recent history.

8 Jun 2010

Over 90% of psychiatric patients treated in community hospitals are cared for in specialty units: Study

Over 90 percent of psychiatric patients who received treatment in community hospitals were cared for in hospital-based psychiatric specialty units, according to a study sponsored by the Substance Abuse and Mental Health Services Administration and the U.S. Agency for Healthcare Research and Quality and published today in Psychiatric Services.

3 Jun 2010

Phase II trial of NUVIGIL Tablets for treatment of schizophrenia fails to meet primary endpoint: Cephalon

Cephalon, Inc. today announced that the primary endpoint was not met in a Phase II clinical trial that examined NUVIGIL (armodafinil) Tablets [C-IV] as an adjunctive therapy for the treatment of the negative symptoms of schizophrenia, which include problems with motivation and emotional withdrawal.

3 Jun 2010

Enrollment and dosing in NeuroDerm's Phase I clinical trial of ND0611 completed

NeuroDerm, Ltd. announced today the successful enrollment and dosing in its Phase I clinical trial of ND0611. ND0611, a proprietary drug formula administered via a dermal patch, is designed to maintain continuous therapeutic levodopa concentrations for improving the treatment of Parkinson's disease.

1 Jun 2010

BPC mobilizes to ensure patient interests are put first in new BC PharmaCare drug review process

On the verge of a BC Government announcement on a new policy on generic medication pricing and a Long Term Pharmacy Agreement, the Better Pharmacare Coalition (BPC) is mobilizing its two million members to ensure Government keeps its promise that patient interests and input are reflected in the new BC PharmaCare drug review process.

31 May 2010

HSV-1 may cause cognitive deficits: Study

Exposure to the common virus that causes cold sores may be partially responsible for shrinking regions of the brain and the loss of concentration skills, memory, coordinated movement and dexterity widely seen in patients with schizophrenia, according to research led by Johns Hopkins scientists.

29 May 2010

New study provides cause-and-effect link between immune system cells and mental illness

A Nobel Prize-winning University of Utah geneticist discovered that bone marrow transplants cure mutant mice who pull out their hair compulsively. The study provides the first cause-and-effect link between immune system cells and mental illness, and points toward eventual new psychiatric treatments.

28 May 2010

Bone marrow transplant cures excessive pathological grooming behavior in mice

Scientists earlier found that mice missing one of a group of core developmental genes known as the Hox genes developed an odd and rather unexpected pathology: the mutant animals groomed themselves compulsively to the point that they were removing their own hair and leaving self-inflicted open sores on their skin. Now, they've found a surprising connection between the Hoxb8 gene and the behavior that looks an awful lot like that of people with an obsessive compulsive spectrum disorder (OCD).

28 May 2010

UCSF scientists discover new stem cell in developing human brain

UCSF scientists have discovered a new stem cell in the developing human brain. The cell produces nerve cells that help form the neocortex - the site of higher cognitive function -- and likely accounts for the dramatic expansion of the region in the lineages that lead to man, the researchers say.

26 May 2010

Researchers use CASL MRI technique to map cerebral blood flow patterns in schizophrenic patients

Researchers in Germany have used a magnetic resonance imaging technique called continuous arterial spin labeling to map cerebral blood flow patterns in schizophrenic patients quickly and without using radiation or contrast agents. Their findings appear in the online edition and July printed issue of the journal Radiology.

26 May 2010

FDA grants priority review for Alkermes' VIVITROL sNDA for opioid dependence

Alkermes, Inc. today announced that the supplemental New Drug Application (sNDA) for VIVITROL® (naltrexone for extended-release injectable suspension) for opioid dependence has been designated a priority review by the U.S. Food and Drug Administration (FDA).

25 May 2010

Obesity is a risk factor for depressive symptoms

Researchers, led by Kerri Boutelle, PhD, associate professor of pediatrics and psychiatry at the University of California, San Diego School of Medicine have found that obesity is a risk factor for depressive symptoms, but not for clinical depression, suggesting that weight status could play a part in the development of depression in some adolescent girls.

25 May 2010

A unique multi-modal atlas of human brain

The Allen Institute for Brain Science announced today that it has launched the Allen Human Brain Atlas, a publicly available online atlas charting genes at work throughout the human brain.

25 May 2010

66% of patients with schizophrenia have extreme trust in their psychiatrists: New survey

According to a new survey sponsored by Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, 80 percent of patients with schizophrenia, a chronic, severe and disabling brain disorder, say their psychiatrists do well or very well in treating them with courtesy and respect. This positive relationship is particularly important in treating schizophrenia as patients and psychiatrists must work closely together to determine appropriate treatment plans that will help patients manage their symptoms and reduce their risk of relapse.

24 May 2010

Smoking cessation treatments effective and safe for people with schizophrenia

In a study published today in the journal Addiction, researchers have determined that treatment for smoking dependence is as effective among people with severe mental illnesses as it is for the general population. Importantly, they also found that offering such treatments does not appear to cause deterioration in mental health.

21 May 2010

Drug trend for children increased 10.8% in 2009 across America

In growing numbers, children across America are adding a dose of medicine to their daily routine. In 2009, drug trend for children – a measure of prescription spending growth – increased 10.8 percent, driven by a 5 percent increase in drug utilization and higher medication costs, according to the Medco 2010 Drug Trend Report. The growth in prescription drug use among children was nearly four times higher than the rise seen in the overall population.

20 May 2010

Targacept commences Phase 2 clinical proof of concept trial of TC-5619 in adults with ADHD

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in adults with attention deficit/hyperactivity disorder (ADHD). TC-5619 is a novel small molecule that is highly selective for the alpha7 neuronal nicotinic receptor, which Targacept refers to as NNR, and was discovered by Targacept scientists using Targacept's proprietary drug discovery platform known as Pentad (TM).

19 May 2010

Causes and treatment options of mental disorders need to be reassessed: JAMA commentary

It is time to reassess mental disorders, recognizing that these are disorders of brain circuits likely caused by development processes, according to a commentary in the May 19 issue of JAMA, a theme issue on mental health.

19 May 2010

Schizophrenia News and Research

Latest Schizophrenia News and Research

NIH awards Aestus $2M SBIR grant for clinical trials of treatment for chronic neuropathic pain

Secondhand smoke exposure associated with psychological distress

FSPs designed to improve residential stability, mental health outcomes for homeless persons with mental illness

Over 90% of psychiatric patients treated in community hospitals are cared for in specialty units: Study

Phase II trial of NUVIGIL Tablets for treatment of schizophrenia fails to meet primary endpoint: Cephalon

Enrollment and dosing in NeuroDerm's Phase I clinical trial of ND0611 completed

BPC mobilizes to ensure patient interests are put first in new BC PharmaCare drug review process

HSV-1 may cause cognitive deficits: Study

New study provides cause-and-effect link between immune system cells and mental illness

Bone marrow transplant cures excessive pathological grooming behavior in mice

UCSF scientists discover new stem cell in developing human brain

Researchers use CASL MRI technique to map cerebral blood flow patterns in schizophrenic patients

FDA grants priority review for Alkermes' VIVITROL sNDA for opioid dependence

Obesity is a risk factor for depressive symptoms

A unique multi-modal atlas of human brain

66% of patients with schizophrenia have extreme trust in their psychiatrists: New survey

Smoking cessation treatments effective and safe for people with schizophrenia

Drug trend for children increased 10.8% in 2009 across America

Targacept commences Phase 2 clinical proof of concept trial of TC-5619 in adults with ADHD

Causes and treatment options of mental disorders need to be reassessed: JAMA commentary

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Schizophrenia News and Research

Latest Schizophrenia News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in